Jennifer SealeyVoyksner - Entero Therapeutics, Senior Development
| ENTO Stock | 0.45 0.03 7.14% |
Executive
Jennifer SealeyVoyksner is Senior Development of Entero Therapeutics,
| Address | 777 Yamato Road, Boca Raton, FL, United States, 33431 |
| Phone | 561 589 7020 |
| Web | https://www.enterothera.com |
Entero Therapeutics, Management Efficiency
The company has return on total asset (ROA) of (0.2707) % which means that it has lost $0.2707 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1528) %, meaning that it created substantial loss on money invested by shareholders. Entero Therapeutics,'s management efficiency ratios could be used to measure how well Entero Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to drop to -3.19. In addition to that, Return On Capital Employed is likely to grow to -4. At this time, Entero Therapeutics,'s Total Assets are very stable compared to the past year. As of the 25th of November 2024, Non Current Assets Total is likely to grow to about 2.3 M, while Intangible Assets are likely to drop about 2.5 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Aaron JD | Cardinal Health | 52 | |
| Kevin Shannon | Inflection Point Acquisition | N/A | |
| MBA MD | Aquestive Therapeutics | 66 | |
| Sherry Korczynski | Aquestive Therapeutics | N/A | |
| Ernest Toth | Aquestive Therapeutics | 65 | |
| Peter Ondishin | Inflection Point Acquisition | 37 | |
| Robert Arnold | Aquestive Therapeutics | N/A | |
| Mary Scherer | Cardinal Health | N/A | |
| Aaron Alt | Cardinal Health | 52 | |
| Eva Gunnlaugsdottir | Alvotech | N/A | |
| Michael Karicher | Sonida Senior Living | 54 | |
| Craig Cowman | Cardinal Health | N/A | |
| Cassie Jung | Aquestive Therapeutics | 45 | |
| Carl MD | Aquestive Therapeutics | 54 | |
| Brad Cochran | Cardinal Health | N/A | |
| Sandra Casaca | Alvotech | N/A | |
| Kenneth Marshall | Aquestive Therapeutics | 65 | |
| Tanya Zharov | Alvotech | 57 | |
| Jenny Steingrimsdottir | Alvotech | N/A | |
| John Adams | Cardinal Health | N/A | |
| Stephen Wargacki | Aquestive Therapeutics | 46 | |
Management Performance
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.27 |
Entero Therapeutics, Leadership Team
Elected by the shareholders, the Entero Therapeutics,'s board of directors comprises two types of representatives: Entero Therapeutics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Entero. The board's role is to monitor Entero Therapeutics,'s management team and ensure that shareholders' interests are well served. Entero Therapeutics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Entero Therapeutics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jack Syage, Chief President | ||
| Jennifer SealeyVoyksner, Senior Development | ||
| Sarah CPA, Chief Officer | ||
| Amy ChandlerSkerkis, QA Affairs | ||
| RPh MBA, CEO Chairman | ||
| Martin MBA, Senior Development |
Entero Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Entero Therapeutics, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 66.34 M | ||||
| Shares Outstanding | 3.25 M | ||||
| Shares Owned By Insiders | 7.20 % | ||||
| Shares Owned By Institutions | 5.98 % | ||||
| Number Of Shares Shorted | 94.02 K | ||||
| Price To Book | 0.07 X | ||||
| EBITDA | (15.74 M) | ||||
| Net Income | (15.79 M) |
Pair Trading with Entero Therapeutics,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Entero Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entero Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Moving against Entero Stock
| 0.66 | MTEM | Molecular Templates | PairCorr |
| 0.62 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.59 | ME | 23Andme Holding | PairCorr |
| 0.59 | TPST | Tempest Therapeutics | PairCorr |
| 0.52 | NKTX | Nkarta Inc | PairCorr |
The ability to find closely correlated positions to Entero Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Entero Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Entero Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Entero Therapeutics, to buy it.
The correlation of Entero Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entero Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entero Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Entero Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entero Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entero Therapeutics,. If investors know Entero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entero Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.04) | Return On Assets (0.27) | Return On Equity (0.15) |
The market value of Entero Therapeutics, is measured differently than its book value, which is the value of Entero that is recorded on the company's balance sheet. Investors also form their own opinion of Entero Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Entero Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entero Therapeutics,'s market value can be influenced by many factors that don't directly affect Entero Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entero Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Entero Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entero Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.